--- title: "Is Prestige Consumer Healthcare (PBH) Still Worth A Look As It Closes LaCorium And Refinances Debt?" type: "News" locale: "en" url: "https://longbridge.com/en/news/293189171.md" description: "Prestige Consumer Healthcare (PBH) is restructuring its balance sheet by closing the LaCorium Health acquisition and refinancing debt via senior notes and a term loan amendment. Despite recent stock volatility, analysts project strong free cash flow of ~$245 million, supporting deleveraging and share buybacks. The company is deemed undervalued with a fair value of $66.80 against a current price of $49.92, though supply chain issues and e-commerce competition remain key risks." datetime: "2026-07-20T09:11:08.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/293189171.md) - [en](https://longbridge.com/en/news/293189171.md) - [zh-HK](https://longbridge.com/zh-HK/news/293189171.md) --- # Is Prestige Consumer Healthcare (PBH) Still Worth A Look As It Closes LaCorium And Refinances Debt? Prestige Consumer Healthcare (PBH) has moved to reshape its balance sheet and international footprint by closing the LaCorium Health acquisition and arranging new debt financing, including a planned senior notes offering and term loan amendment. See our latest analysis for Prestige Consumer Healthcare. The LaCorium deal and new debt plans come at a time when Prestige Consumer Healthcare’s shares trade at US$49.92. The stock has posted a 6.28% 1 month share price return but a year to date share price decline of 18.46%, alongside a 1 year total shareholder return that is down 34.12%. This points to pressure on longer term holders even as shorter term momentum has picked up slightly. If you want to broaden your watchlist beyond OTC healthcare, this may be a moment to scan for other opportunities in companies with strong balance sheets through the solid balance sheet and fundamentals stocks screener (47 results) So are Prestige Consumer Healthcare’s latest moves a sign that the underlying OTC portfolio and cash generation can support more debt and acquisitions, or is the share price reacting more to changing sentiment around leverage and growth plans? ## Most Popular Narrative: 25.3% Undervalued Prestige Consumer Healthcare’s most followed narrative anchors on a fair value of $66.80, which sits well above the last close at $49.92 and frames the debate around how much future cash generation is already priced in. > _Prestige's strong and consistent free cash flow generation (~$245 million projected for the year) provides financial flexibility for continued deleveraging and opportunistic share repurchases, supporting future earnings per share (EPS) growth and value for shareholders._ Read the complete narrative. The core of this valuation story is straightforward yet rests on several assumptions. Steady revenue expansion, higher margins, and fewer shares all feed into a richer earnings base. Readers may be interested in how those moving parts combine into that fair value and what kind of profit multiple underpins it. **Result: Fair Value of $66.80 (UNDERVALUED)** Have a read of the narrative in full and understand what's behind the forecasts. However, there are still clear pressure points for Prestige Consumer Healthcare, including ongoing supply chain issues around key brands and heavier competition in e commerce channels that could challenge this upside story. Find out about the key risks to this Prestige Consumer Healthcare narrative. ## Next Steps With both risks and rewards on the table for Prestige Consumer Healthcare, do you want to move quickly and test the narrative against the numbers yourself? Start by weighing the 4 key rewards and 1 important warning sign ## Looking for more investment ideas beyond Prestige Consumer Healthcare? If Prestige Consumer Healthcare has sharpened your focus, do not stop here. Broaden your search with other focused stock ideas that fit your style and risk comfort. - Target potential mispricings by reviewing companies highlighted in the 48 high quality undervalued stocks that some investors might be overlooking. - Secure income focused opportunities by checking out the 8 dividend fortresses built around companies with higher yielding payouts. - Dial down portfolio risk by scanning the 81 resilient stocks with low risk scores for businesses screened on more resilient characteristics. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### **New:** Manage All Your Stock Portfolios in One Place We've created the **ultimate portfolio companion** for stock investors, **and it's free.** • Connect an unlimited number of Portfolios and see your total in one currency • Be alerted to new Warning Signs or Risks via email or mobile • Track the Fair Value of your stocks Try a Demo Portfolio for Free ### Related Stocks - [PBH.US](https://longbridge.com/en/quote/PBH.US.md) ## Related News & Research - [Prestige Consumer Healthcare (PBH) Projected to Announce Quarterly Earnings on Thursday](https://longbridge.com/en/news/294339087.md) - [Prestige Consumer Healthcare unit issues USD 400 million of 6.25% senior notes due 2034](https://longbridge.com/en/news/292810278.md) - [How investors can navigate the healthcare sector](https://longbridge.com/en/news/293960711.md) - [BioAdaptives Inc. Reports Scaling of E-Commerce Footprint and Consumer Reach for MyndSystem(TM) Nootropic Platform | BDPT Stock News](https://longbridge.com/en/news/294238397.md) - [WSO: Revenue up, margins down; e-commerce and Sunbelt expansion drive future growth](https://longbridge.com/en/news/294206665.md)